BiogenMEX:BIIB 59 OCF Margin % is 26.05% as of Mar. 2026, which is 19% below its 10-year median of 32.31. GuruFocus rates MEX:BIIB with a GF Score™ of 59/100 and a GF Value™ of MXN3,205.98 (Fairly Valued). The stock has 7 warning signs investors should review. Among 959 Drug Manufacturers companies, Biogen ranks better than 88.32% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Biogen's Cash Flow from Operations for the
three
months ended in Mar. 2026 was MXN11,640 Mil. Biogen's Revenue for the
three
months ended in Mar. 2026 was MXN44,681 Mil. Therefore, Biogen's OCF Margin % for the quarter that ended in Mar. 2026 was 26.05%.
The historical rank and industry rank for Biogen's OCF Margin % or its related term are showing as below:
MEX:BIIB'
s OCF Margin % Range Over the Past 10 Years
Min: 13.61 Med: 32.31 Max: 49.23
Current: 25.93
During the past 13 years, the highest OCF Margin % of Biogen was 49.23%. The lowest was 13.61%. And the median was 32.31%.
MEX:BIIB's OCF Margin % is ranked better than 88.32% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs MEX:BIIB: 25.93
Biogen OCF Margin % Related Terms
Biogen OCF Margin % Historical Data
* Premium members only.
The historical data trend for Biogen's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BIIB vs OGN, AMRN, SCLX: OCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Biogen's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Biogen's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (MEX:BIIB) has a OCF Margin % of 26.05% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biogen and its competitors. This is 19% below median its historical median of 32.31. Over the past decade, Biogen's OCF Margin % has ranged from 13.61 to 49.23. According to the industry distribution chart, Biogen ranks #112 out of 959 companies in the Drug Manufacturers industry, placing it in the top 11.7%.
Is Biogen's OCF Margin % too high?
Biogen's current OCF Margin % of 26.05% is 19% below median its 10-year median of 32.31. Over the past 10 years, this metric has ranged from a low of 13.61 to a high of 49.23. The Drug Manufacturers industry median OCF Margin % is 9.95. Biogen's value of 26.05% is 161.8% above this industry median. Based on the distribution chart, Biogen ranks #112 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biogen has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's OCF Margin % compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #112 out of 959 companies for OCF Margin %. This places Biogen in the top 12% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.95. Biogen's value of 26.05% is 161.8% above this benchmark. Historically, Biogen's own OCF Margin % has ranged from 13.61 to 49.23 over the past decade. While the company's 10-year median is 32.31 vs. the industry median of 9.95, Biogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogen's current OCF Margin % of 26.05% is 161.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Biogen and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current OCF Margin % is 26.05%, which is 19% below median its own 10-year median of 32.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (MEX:BIIB) is currently considered Fairly Valued. The stock's GF Value™ is MXN3,205.98, compared to a current price of MXN3,335.50 — trading 4% above its estimated fair value. The current OCF Margin % is 26.05%, which is 19% below median its 10-year median of 32.31 and 161.8% above the Drug Manufacturers industry median of 9.95. Biogen's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Biogen (MEX:BIIB), the current OCF Margin % is 26.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (MEX:BIIB) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of MXN3,335.50 is trading 4% above its estimated GF Value™ of MXN3,205.98.
GuruFocus considers Biogen to be Fairly Valued.
Key valuation signals for MEX:BIIB:
OCF Margin %: 26.05% (19% below median its 10-year median of 32.31)
GF Value™: MXN3,205.98 vs. price of MXN3,335.50 (4% above fair value)
Industry Position: 161.8% above the Drug Manufacturers median (#112 of 959)
No single metric tells the full story. See the MEX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
59GF Score
Get the complete analysis for MEX:BIIB
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BIIB has been successfully added to your 
